May 20th, 12:30 PM

Sentinel Lymph Node Biopsy Does Not Improve Disease-Specific Survival in Elderly Patients with Intermediate Thickness Melanoma

Kate H. Dinh  
*University of Massachusetts Medical School*

Mary E. Maloney  
*University of Massachusetts Medical School*

Dori Goldberg  
*University of Massachusetts Medical School*

See next page for additional authors

Follow this and additional works at: [https://escholarship.umassmed.edu/cts_retreat](https://escholarship.umassmed.edu/cts_retreat)

Part of the *Dermatology Commons, Diagnosis Commons, Geriatrics Commons, Neoplasms Commons, Oncology Commons, Pathology Commons, Skin and Connective Tissue Diseases Commons*, and the *Translational Medical Research Commons*

Dinh, Kate H.; Maloney, Mary E.; Goldberg, Dori; Deng, April; Sullivan, Mary E.; and Lambert, Laura A., "Sentinel Lymph Node Biopsy Does Not Improve Disease-Specific Survival in Elderly Patients with Intermediate Thickness Melanoma" (2014). *UMass Center for Clinical and Translational Science Research Retreat*. 36.  
[https://escholarship.umassmed.edu/cts_retreat/2014/posters/36](https://escholarship.umassmed.edu/cts_retreat/2014/posters/36)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Presenter Information
Kate H. Dinh, Mary E. Maloney, Dori Goldberg, April Deng, Mary E. Sullivan, and Laura A. Lambert

Comments
Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

This is available at eScholarship@UMMS: https://escholarship.umassmed.edu/cts_retreat/2014/posters/36
Sentinel Lymph Node Biopsy Does Not Improve Disease-Specific Survival in Elderly Patients with Intermediate Thickness Melanoma

Kate H. Dinh, M.D., Mary Maloney, M.D., Dori Goldberg, M.D., April Deng, M.D., Mary Sullivan, N.P., Laura Lambert, M.D., Giles Whalen, M.D., Jennifer LaFemina, M.D.

1Department of Surgery, 2Division of Dermatology, 3Department of Pathology; University of Massachusetts Medical School; Worcester, MA
Contact: kate.dinh@umassmemorial.org

Objective: To determine whether sentinel lymph node biopsy (SLNB) is associated with improved disease-specific survival among elderly patients with intermediate-thickness melanoma

Design: Retrospective cohort study of prospectively-maintained tumor registry

Setting: Single institution tertiary care center

Patients: Adults ≥ 70 years of age, who underwent surgical intervention for melanoma from 2000-2013

Main Outcome Measures: The primary outcomes were overall survival (OS) and disease-free survival (DFS). Other clinicopathologic variables measured included age, gender, anatomic site, histologic type, tumor thickness, presence of adverse features, receipt and result of SLNB, and receipt of completion lymph node dissection (CLND).

Results: Ninety-one patients (mean age 80 years, 54% male) underwent wide excision of an intermediate-thickness melanoma. Forty-nine patients (54%) received a SLNB. Seven of these biopsies (14%) were positive, and five patients (71%) went on to receive CLND. Five-year OS was 41% in patients who did not receive SLNB and 52% in patients who did receive SLNB (Fig. 1A). However, 5-year DFS was 79% in patients who did not receive SLNB and 77% in patients who did receive SLNB (Fig. 1B).

Conclusions: Among elderly patients with intermediate-thickness melanoma, patients who received SLNB had higher 5-year OS than those who did not receive SLNB. However, the 5-year DFS is similar between the two groups, which suggests that the OS differences are related to non-melanoma factors. Routine SLNB for intermediate-thickness melanoma patients may not significantly change the outcome for this age group, and clinical decision-making should consider individual patient comorbidities and goals of care.

Figure 1. Survival of patients with intermediate-thickness melanoma

Kaplan-Meier curves of overall (A) and disease-free (B) survival, among patients with intermediate-thickness melanoma, who either did receive sentinel lymph node biopsy (SLNB+) or did not receive sentinel lymph node biopsy (SLNB-).